IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Christopher F. Clarbone, et al DEC 2 3 2004

Serial No.

-10/079,452

Filed: February 20, 2002

N-SUBSTITUTED NONARYL-HETEROCYCLIC

NMDA/NR2B ANTAGONISTS

.....

Art Unit: 1624 Examiner: Deepak R. Rao

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

12 Date 12/20/2004

Computer generated form "IDS Letter" (IDS Folder), Merck & Co., Inc., 10/21/2004



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION				
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			
If this is inconvenient, additional copies will be submitted upon requ	est.				
6. In accordance with 37 C.F.R. 1.97, (check one)					
the attached information is filed within three months of the filing	date of the captioned case.				
the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.					
the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p					
the undersigned certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.					
the undersigned certifies that no item of information contained in a communication from a foreign patent office in a counterpart for person signing the certification after making reasonable inquiry, C.F.R. 1.56(c) more than three months prior to the filing of this S	reign application, and, to the was known to any individua	e knowledge of the			
	Deep estfully submitted				

By: Mitul I. Desai

Attorney For Applicant(s)

Reg. No. 46,661

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-3190

Date: December 20, 2004

DEC 2 3 2004 8

` _			1 300 2 0 1	2001 101	Tatell and Tradellark Office, 0.3 Del ARTIMENT OF COMMERCE		
Substitute for form 1449A/PTO SUPPLEMENTA			EMENTA 2	COMPLETE IF KNOWN			
	INFORMATION	DIS	CLOSURE	Application Number	10/079,452		
				Filing Date	February 20, 2002		
STATEMENT BY APPLICAN		FLICANI	First Named Inventor	Christopher F. Claiborne, et al.			
				Group Art Unit	1624		
(use as many sheets as necessary)		iecessary)	Examiner Name	Deepak R. Rao			
Shee	t 1	of	2	Attorney Docket Number	20832Y	_	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
		4,197,304		Stefan Sanczuk, et al.	04/08/1980			
	-							
			-					
	_							
			-					
				-				
		4						
					<u> </u>			

	FOREIGN PATENT DOCUMENTS					
F	Examiner Cite		Foreign Patent Document		Name of Detector on Applicant	Date of Publication of
Examiner Initials*	No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
		DT	Offenlegungsschrift 23 41 965		Dr. Adolf Langbein, et al.	03/06/1975
			·			

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DEC 2 3 Substitute for form 1449B/PTO SUPPLEMENTAL Application Number **COMPLETE IF KNOWN** 10/079,452 Filing Date February 20, 2002 STATEMENT BY APPLICANT First Named Inventor Christopher F. Claiborne, et al. Group Art Unit 1624 (use as many sheets as necessary) **Examiner Name** Deepak R. Rao 2 2 Sheet of Attorney Docket Number 20832Y

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
		ISABELLE PARROT, et al., Synthesis of Substituted 3-Amino-6-arylpyridazines via Suzuki Reaction, Vol. No. 7, pp. 1163-1168, (1999).				
		J. MORAGUES, et al., <u>Dopaminergic Activity in a Series of N-Substituted 2-Aminopyrimidines</u> , Vol. No. 35, pp. 951-964, (1980).				
		·				

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.